Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Mesoblast is a small cap biotech company with listings on both the ASX and the Nasdaq. The company has acquired the rights to develop and commercialize certain regenerative medicine technologies aimed at innovative ways of treating inflammatory diseases. Of their product pipeline, three product candidates are currently in phase three trials, with the first drug in the FDA approval application process and a possible U.S. launch date in early fiscal 2021. The company has sold the rights to develop and commercialize some of its technologies in Japan, Europe and China from which it earns milestone and ongoing licence revenues once the products are marketed. Mesoblast is currently in the R&D phase and is loss-making.
Melbourne, VIC, 3000, Australia